NLRP3 and early-onset autosomal dominant Alzheimer disease: It was experimentally proven that preventing the development of local insulin resistance by blocking NLRP3 inflammasomes and mediated neuroinflammation should be considered a pathogenetically grounded approach to correcting cognitive disorders in Alzheimer’s disease.